β-1,4-Gal-T3 Inhibitors

Chemical inhibitors of β-1,4-Gal-T3 operate through various mechanisms to hinder the enzymatic function of this protein. UDP functions as a competitive inhibitors. UDP competes with the natural substrate UDP-galactose, preventing it from binding to the active site of β-1,4-Gal-T3, thus obstructing the galactosylation process that the enzyme is responsible for catalyzing. Similarly, Phenyl 2-acetamido-2-deoxy-β-D-galactopyranoside mimics the structure of the natural lactose substrate, occupying the active site of β-1,4-Gal-T3 and thereby precluding the enzyme's action on its intended substrate. On the other hand, Galactostatin blocks the enzyme's galactosyltransferase activity by binding directly to its active site, which blocks the access of natural substrates to the catalytic domain of the enzyme.

Other inhibitors interfere with the function of β-1,4-Gal-T3 by targeting the availability of substrates or the enzyme's processing pathways. Castanospermine and Deoxynojirimycin inhibit glucosidases, enzymes that are critical for the proper folding and processing of glycoproteins, which are necessary substrates for β-1,4-Gal-T3. This results in a decreased availability of properly folded glycoproteins for the enzyme. Similarly, Swainsonine targets mannosidase II, leading to the accumulation of misprocessed glycoproteins, which may limit substrate access for β-1,4-Gal-T3. PDMP inhibits the synthesis of glycosphingolipids, which are substrates for β-1,4-Gal-T3, thereby reducing the enzyme's activity due to substrate scarcity. Finally, AMP-DNM competes with the natural nucleotide sugar donor, while Kifunensine and Nojirimycin lead to an accumulation of non-processed glycoproteins, further saturating the enzyme with substrates that are not the intended targets for galactosylation, thus affecting the efficiency of β-1,4-Gal-T3.